Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials.
Expert Opin Emerg Drugs
; 27(2): 187-209, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1965653
ABSTRACT
INTRODUCTION:
Ventilatory management and general supportive care of acute respiratory distress syndrome (ARDS) in the adult population have led to significant clinical improvements, but morbidity and mortality remain high. Pharmacologic strategies acting on the coagulation cascade, inflammation, oxidative stress, and endothelial cell injury have been targeted in the last decade for patients with ARDS, but only a few of these have shown potential benefits with a meaningful clinical response and improved patient outcomes. The lack of availability of specific pharmacologic treatments for ARDS can be attributed to its complex pathophysiology, different risk factors, huge heterogeneity, and difficult classification into specific biological phenotypes and genotypes. AREAS COVERED In this narrative review, we briefly discuss the relevance and current advances in pharmacologic treatments for ARDS in adults and the need for the development of new pharmacological strategies. EXPERT OPINION Identification of ARDS phenotypes, risk factors, heterogeneity, and pathophysiology may help to design clinical trials personalized according to ARDS-specific features, thus hopefully decreasing the rate of failed clinical pharmacologic trials. This concept is still under clinical investigation and needs further development.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
Type of study:
Prognostic study
/
Reviews
Limits:
Humans
Language:
English
Journal:
Expert Opin Emerg Drugs
Journal subject:
Drug Therapy
Year:
2022
Document Type:
Article
Affiliation country:
14728214.2022.2105833
Similar
MEDLINE
...
LILACS
LIS